Manuel Weber1,2, Walter Jentzen3,4, Regina Hofferber3,4, Ken Herrmann3,4, Wolfgang Peter Fendler3,4, Christoph Rischpler3,4, Lale Umutlu4,5, Maurizio Conti6, Pedro Fragoso Costa3,4, Miriam Sraieb3,4, David Kersting3,4. 1. Department of Nuclear Medicine, University of Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45122, Essen, Germany. manuel.weber@uk-essen.de. 2. University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital, Essen, Germany. manuel.weber@uk-essen.de. 3. Department of Nuclear Medicine, University of Duisburg-Essen, University Hospital Essen, Hufelandstrasse 55, 45122, Essen, Germany. 4. University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital, Essen, Germany. 5. Department of Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. 6. Siemens Medical Solutions USA, INC, Erlangen, Germany.
Abstract
BACKGROUND: The superior accuracy and sensitivity of 18F-FDG-PET/CT in comparison to morphological imaging alone leads to an upstaging in up to 30% of lymphoma patients. Novel digital PET/CT scanners might enable to reduce administered tracer activity or scan time duration while maintaining diagnostic performance; this might allow for a higher patient throughput or a reduced radiation exposure, respectively. In particular, the radiation exposure reduction is of interest due to the often young age and high remission rate of lymphoma patients. METHODS: Twenty patients with (suspected) lymphoma (6 for initial staging, 12 after systemic treatment, 2 in suspicion of recurrence) sequentially underwent 18F-FDG-PET/CT examinations on a digital PET/CT (Siemens Biograph Vision) with a total scan time duration of 15 min (reference acquisition protocol) and 5 min (reduced acquisition protocol) using continuous-bed-motion. Both data sets were reconstructed using either standalone time of flight (TOF) or in combination with point spread function (PSF), each with 2 and 4 iterations. Lesion detectability by blinded assessment (separately for supra- and infradiaphragmal nodal lesions and for extranodal lesions), lesion image quantification, and image noise were used as metrics to assess diagnostic performance. Additionally, Deauville Score was compared for all patients after systemic treatment. RESULTS: All defined regions were correctly classified in the images acquired with reduced emission time, and therefore, no changes in staging were observed. Lesion quantification was acceptable, that is, mean absolute percentage deviation of maximum and peak standardized uptake values were 6.8 and 6.4% (derived from 30 lesions). A threefold reduction of scan time duration led to an increase in image noise from 7.1 to 11.0% (images reconstructed with 4 iterations) and from 4.7 to 7.2% (images reconstructed with 2 iterations). No deviations in Deauville Score were observed. CONCLUSION: These results suggest that scan time duration or administered tracer activity can be reduced threefold without compromising diagnostic performance. Especially a reduction of administered activity might allow for a lower radiation exposure and better health economics. Larger trials are warranted to confirm our results.
BACKGROUND: The superior accuracy and sensitivity of 18F-FDG-PET/CT in comparison to morphological imaging alone leads to an upstaging in up to 30% of lymphomapatients. Novel digital PET/CT scanners might enable to reduce administered tracer activity or scan time duration while maintaining diagnostic performance; this might allow for a higher patient throughput or a reduced radiation exposure, respectively. In particular, the radiation exposure reduction is of interest due to the often young age and high remission rate of lymphomapatients. METHODS: Twenty patients with (suspected) lymphoma (6 for initial staging, 12 after systemic treatment, 2 in suspicion of recurrence) sequentially underwent 18F-FDG-PET/CT examinations on a digital PET/CT (Siemens Biograph Vision) with a total scan time duration of 15 min (reference acquisition protocol) and 5 min (reduced acquisition protocol) using continuous-bed-motion. Both data sets were reconstructed using either standalone time of flight (TOF) or in combination with point spread function (PSF), each with 2 and 4 iterations. Lesion detectability by blinded assessment (separately for supra- and infradiaphragmal nodal lesions and for extranodal lesions), lesion image quantification, and image noise were used as metrics to assess diagnostic performance. Additionally, Deauville Score was compared for all patients after systemic treatment. RESULTS: All defined regions were correctly classified in the images acquired with reduced emission time, and therefore, no changes in staging were observed. Lesion quantification was acceptable, that is, mean absolute percentage deviation of maximum and peak standardized uptake values were 6.8 and 6.4% (derived from 30 lesions). A threefold reduction of scan time duration led to an increase in image noise from 7.1 to 11.0% (images reconstructed with 4 iterations) and from 4.7 to 7.2% (images reconstructed with 2 iterations). No deviations in Deauville Score were observed. CONCLUSION: These results suggest that scan time duration or administered tracer activity can be reduced threefold without compromising diagnostic performance. Especially a reduction of administered activity might allow for a lower radiation exposure and better health economics. Larger trials are warranted to confirm our results.
Authors: Joyce van Sluis; Ronald Boellaard; Ananthi Somasundaram; Paul van Snick; Ronald Borra; Rudi Dierckx; Gilles Stormezand; Andor Glaudemans; Walter Noordzij Journal: J Nucl Med Date: 2019-06-28 Impact factor: 10.057
Authors: Brenda F Kurland; Lanell M Peterson; Andrew T Shields; Jean H Lee; Darrin W Byrd; Alena Novakova-Jiresova; Mark Muzi; Jennifer M Specht; David A Mankoff; Hannah M Linden; Paul E Kinahan Journal: J Nucl Med Date: 2018-10-25 Impact factor: 10.057
Authors: Isabel Rauscher; Wolfgang P Fendler; Thomas A Hope; Andrew Quon; Stephan G Nekolla; Jeremie Calais; Antonia Richter; Bernhard Haller; Ken Herrmann; Wolfgang A Weber; Johannes Czernin; Matthias Eiber Journal: J Nucl Med Date: 2019-07-19 Impact factor: 10.057
Authors: David Kersting; Walter Jentzen; Miriam Sraieb; Pedro Fragoso Costa; Maurizio Conti; Lale Umutlu; Gerald Antoch; Michael Nader; Ken Herrmann; Wolfgang Peter Fendler; Christoph Rischpler; Manuel Weber Journal: EJNMMI Phys Date: 2021-02-15
Authors: David Kersting; Stephan Settelmeier; Ilektra-Antonia Mavroeidi; Ken Herrmann; Robert Seifert; Christoph Rischpler Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923
Authors: Pedro Fragoso Costa; Walter Jentzen; Alissa Brahmer; Ilektra-Antonia Mavroeidi; Fadi Zarrad; Lale Umutlu; Wolfgang P Fendler; Christoph Rischpler; Ken Herrmann; Maurizio Conti; Robert Seifert; Miriam Sraieb; Manuel Weber; David Kersting Journal: BMC Cancer Date: 2022-08-18 Impact factor: 4.638
Authors: Nicolas Aide; Charline Lasnon; Adam Kesner; Craig S Levin; Irene Buvat; Andrei Iagaru; Ken Hermann; Ramsey D Badawi; Simon R Cherry; Kevin M Bradley; Daniel R McGowan Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-03 Impact factor: 9.236